---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-103034"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:30:32.132101+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Seres Therapeutics reports FY 2025 net income of $5.7M from continuing ops; cash runway through Q3 2026

## Summary
- Full-year 2025 net income from continuing ops $5.7M vs net loss of $125.8M in 2024; Q4 net loss $15.3M.
- Cash and equivalents $45.8M as of Dec 31, 2025; expects to fund operations through Q3 2026.
- SER-155 IST for immune checkpoint-related enterocolitis fully enrolled; data expected Q2 2026.
- SER-603 for IBD in IND-enabling activities; seeking partnerships for clinical advancement.
- Richard Kender appointed Executive Chair and interim CEO; company prioritized inflammatory/immune programs.

## SEC filing metadata
- accession: 0001193125-26-103034
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103034/0001193125-26-103034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312526103034/d98522d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-103034
- JSON: https://secwatch.observer/filing/0001193125-26-103034.json
- Plain text: https://secwatch.observer/filing/0001193125-26-103034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.